Endometriosis \[MIM 131200\] is a disease affecting 6-10% of women of reproductive age[@R1] with significant annual health costs[@R2] and health burden for individuals[@R3],[@R4]. Common symptoms include chronic pelvic pain, severe dysmenorrhea (painful periods), and sub-fertility. The causes of endometriosis remain uncertain despite over 50 years of hypothesis-driven research. Disease severity is classified using the revised American Fertility Society (rAFS) system[@R5], assigning patients to one of four stages (I--IV, minimal-severe) based on lesion size and associated pelvic adhesions. However, it remains unclear whether the disease progresses through these stages, and it has been suggested that small lesions (stages I-II) represent an epiphenomenon rather than a disease entity[@R6]. Endometriosis risk is influenced by genetic factors[@R7]-[@R14], with heritability estimated around 51%[@R9].

We genotyped 3,194 unrelated cases with surgically confirmed endometriosis, recruited by the International Endogene Consortium, IEC (QIMR, Australia dataset = 2,270; Oxford, UK dataset = 924)[@R15], using the Illumina Human670Quad Beadarray (**Online Methods**). Disease stage was assessed from surgical records using the rAFS classification system[@R5],[@R15] and grouped into two phenotypes: stage A (stage I-II or some ovarian disease plus a few adhesions; N = 1,686, 52.7%), and stage B (stage III--IV disease; N = 1,364, 42.7%), or unknown (N = 144, 4.6%) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Illumina Human610Quad control genotypes for QIMR cases were available for 1,870 individuals in an adolescent twin study[@R16],[@R17]. For Oxford cases, Illumina Human1M-Duo genotypes for 5,190 UK population controls were obtained from the Wellcome Trust Case Control Consortium (WTCCC2). Although endometriosis affects women, Australian and UK control sets included men to maximise power of association detection on autosomal chromosomes (**Online Methods**). No significant autosomal allele frequency differences were detected between male and female control samples ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), indicating that association signals would not be influenced by differing female/male ratio in the cases and controls.

Studies to date have established that endometriosis is heritable, but have not addressed genetic burden for different disease stages. We used the GWA data to assess genetic loading in cases in two complementary ways. Using a novel method[@R18] we estimated the proportion of variation in case-control status that can be explained by considering all SNPs simultaneously through inference of distant relatedness from marker data and comparing it to case-control status (**Online Methods**). The proportion of variation in case-control status explained by the GWA data was highly significant for both "all" and stage B endometriosis ([Table 1](#T1){ref-type="table"}; [Supplementary Table 2](#SD1){ref-type="supplementary-material"}**)**. The estimate for stage B (0.34, SE: 0.04) was significantly higher than for stage A (0.15, SE: 0.04 ([Table 1](#T1){ref-type="table"})).

We also assessed the genetic loading of the different stages using a "prediction" approach (**Online Methods**)[@R19] in which we used the Oxford data as a "discovery" set to identify increasingly large SNP sets ranked on significance of association ("allele specific scores"), and used these scores to predict disease status in "target" samples from QIMR. The discovery and target sets were then reversed ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Oxford "all" endometriosis predicted endometriosis in the QIMR sample, with the smallest *P* value (8.4 × 10^−6^) obtained for a score set including \~75% of SNPs ([Fig. 1](#F1){ref-type="fig"}). This result was highly significant, although the proportion of variance explained was small (maximum Nagelkerke R^2^ of 0.007; 0.7% of the variance). For stage B cases the proportion of variance explained by most score sets was higher (e.g. the score set including the \~20% most associated SNPs (*P* = 3.5 × 10^−7^) explained 1.3% of the variance, consistent with a greater (polygenic) genetic loading for stage B disease.

We performed two GWA analyses stratified by dataset (QIMR and Oxford) using: 1) "all" 3,194 endometriosis cases, and 2) 1,364 stage B cases, given their substantially greater genetic loading (**Online Methods**). For 'all' endometriosis, the strongest signal was observed for rs12700667 in an inter-genic region on chromosome 7p15.2 (*P* = 2.6 × 10^−7^, OR = 1.22 (1.13-1.32), [Table 2](#T2){ref-type="table"}). As predicted from our quantitative genetic analyses, stronger signals of association across the genome were observed for stage B disease compared to 'all' endometriosis ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}**)**. The 7p15.2 signal for stage B endometriosis was considerably stronger producing *P* = 1.5 × 10^−9^, OR = 1.38 (1.24-1.53) ([Table 2](#T2){ref-type="table"}) for rs12700667, and *P* = 6.0 × 10^−8^, OR = 1.34 (1.21-1.49) for nearby rs7798431 (r^2^ = 0.87). A second strong association was found for rs1250248 (2q35) within the *FN1* gene (*P* = 3.2 × 10^−8^) ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Results for SNPs rs12700667, rs7798431 and rs1250248 remained genome-wide significant after adjustment for multiple testing in the two non-independent GWA analyses via permutation (**Online Methods**). Only one of the permuted GWAs produced an independent *P* value less than that observed for rs12700667 (*P* = 0.001). The SNPs rs12700667 and rs7798431 lie in a narrow region of strong LD (r^2^ \> 0.8) that extends for approximately 48 kb. Following imputation with 1000 Genomes and HapMap data ([Fig 2](#F2){ref-type="fig"}; **Supplementary Methods)**, conditioning on the effect of rs12700667 in logistic regression analysis showed no other independent associations with "all" or stage B endometriosis in the region.

In addition to the three genome-wide significant SNPs, we genotyped 70 SNPs producing nominal evidence of association with "all" (*P* \< 1.0 × 10^−4^) or stage B endometriosis (*P* \<1.0 × 10^−4^ in stage B and *P* \<1.0 × 10^−3^ in "all" endometriosis analyses; **Online Methods**) in an independent IEC dataset encompassing 2,392 self-reported surgically confirmed cases from the Nurses' Health Study II (NHSII) and 2,271 controls from GWAs of breast cancer[@R20] and kidney function from the Nurses' Health Study (NHS) I and II. Stage information was not available for NHSII cases, but the proportion likely to have stage B disease has been estimated at approximately 40%[@R21], similar to that observed in the QIMR case set ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Association with "all" endometriosis for the two SNPs on 7p15.2 was replicated in the US dataset, with *P* = 1.2 × 10^−3^, OR 1.17 (1.06-1.28) for rs12700667 and *P* = 1.6 × 10^−3^, OR = 1.17 (1.06-1.28) for rs7798431 ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). There was no evidence (nominal *P* ≤ 0.05) for replication of rs12540248 (*FN1*), or association with the remaining 70 SNPs ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}).

Analysis of all 5,586 cases and 9,331 controls from the combined QIMR, Oxford and NHS cohorts further confirmed association between "all" endometriosis and 7p15.2, producing *P* values of 1.4 × 10^−9^ (OR = 1.20 (1.13-1.27)) for rs12700667 and 1.1 × 10^−7^ (OR = 1.18 (1.11-1.25)) for rs7798431 ([Table 2](#T2){ref-type="table"}). Although effect sizes from discovery datasets may be inflated[@R22], the similarity of ORs for "all" endometriosis in our discovery (GWA) and replication datasets ([Table 2](#T2){ref-type="table"}), suggests this type of bias has not played a major role. Assuming the estimated OR of 1.20 and allele frequency of 0.74 for the rs12700667 A allele, a multiplicative risk model, and a population prevalence of 8%[@R10],[@R21],[@R23], the estimated percentage of "all" endometriosis variance explained by rs12700667 is 0.36 (or 0.69% of the estimated 51% heritability of endometriosis[@R9]).

The associated SNPs are located in a \~924 kb inter-genic region containing at least one non-coding RNA (AK057379), predicted transcripts and regulatory elements and a miRNA (hsa-mir-148a) \~88 kb upstream of rs12700667. The closest gene *NFE2L3*, highly expressed in placenta, is located \~331 kb downstream of rs12700667. Two endometriosis candidate genes *HOXA10* and *HOXA11*[@R24],[@R25], members of the homeobox A family of transcription factors that play a role in uterine development, lie \~1.35 Mb downstream.

Among reported candidate gene associations for endometriosis[@R14] the only gene with a *P* value \<10^−3^ for SNPs in the GWA data was *PGR* on chromosome 11 ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}), but the result for this SNP was not significant in the replication stage. A recent GWA scan in Japanese women reported significant association of endometriosis with rs10965235 (*P* = 5.8 × 10^−12^, OR = 1.44) located on chromosome 9p21, and possible associations with rs13271465 on 8p22 and rs16826658 on 1p36[@R26]. The Japanese GWA study did not report our 7p15.2 signal among their 100 top SNPs followed up for replication, but with 1,423 cases and 1,318 controls they would have had only 13% power to detect the effect of rs12700667 with *P* ≤ 1.8 × 10^−4^ (**Online Methods**). We found no evidence for association with rs10965235 (which is monomorphic in individuals of European descent reflecting the different genetic ("ancestral") backgrounds between the studies) or any other SNP in LD (r^2^ \> 0.5 in HapMap JPT) in the QIMR/Oxford data ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). We also found no evidence of association to 8p22. We did find evidence for replication of SNP rs7521902 on 1p36 close to *WNT4* for both "all" endometriosis (*P* = 9.0 × 10^−5^; OR = 1.16 (1.08-1.25)) and stage B (*P* = 7.5 × 10^−6^; OR = 1.25 (1.13-1.38)), the stronger signal in stage B providing additional empirical evidence for the benefit of examining stage B cases. Importantly, meta-analysis of the QIMR and Oxford "all" endometriosis OR with the reported Japanese OR of 1.25 (1.12-1.39) for rs7521902 produced a genome-wide significant *P* value of 4.2 × 10^−8^ (OR = 1.19 (1.12-1.27)). The frequency of the rs7521902 risk allele (A) was 0.57 and 0.51 in the Japanese GWAs cases and controls, and 0.26 and 0.24 in our combined GWAs cases and controls. *WNT4* is important for development of the female reproductive tract[@R27], ovarian follicle development and steroidogenesis[@R28],[@R29], and a plausible biological candidate.

We have identified a novel locus on chromosome 7p15.2 significantly associated with risk of endometriosis in women of European ancestry and confirm a previously reported suggestive association for SNPs close to the *WNT4* locus. Our analyses also demonstrate a higher genetic loading for moderate-severe (stage B) endometriosis, and consistent with these results the strongest association signals were observed with stage B disease. Our predictive modelling demonstrates there are additional common variants contributing to risk for this disease and that future larger studies enriched for laparoscopically-confirmed moderate-severe cases will be better powered to identify risk loci and aberrant pathways contributing to the development of endometriosis.
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ONLINE METHODS {#S2}
==============

GWA samples and phenotyping {#S3}
---------------------------

For the current study, 2,351 surgically-confirmed endometriosis cases were drawn from individuals recruited by The Queensland Institute of Medical Research (QIMR)[@R30] and a further 1,030 cases from individuals recruited by the Oxford Endometriosis Gene (OXEGENE) study. Controls consisted of 1,870 individuals recruited by QIMR[@R31],[@R32], and a further 6,000 individuals provided by the Wellcome Trust Case Control Consortium 2 (WTCCC2) (**Supplementary Methods**). Approval for the studies was obtained from the QIMR HREC and the Australian Twin Registry and the Oxford regional Multi-centre and Local Research Ethics Committees. Informed consent was obtained from all participants prior to testing.

GWA genotyping and quality control {#S4}
----------------------------------

QIMR and Oxford cases and QIMR controls were genotyped at deCODE Genetics on Illumina 670Quad (cases) and 610Quad (controls) BeadChips (Illumina Inc, San Diego, USA). The WTCCC2 controls were genotyped at the Wellcome Trust Sanger Institute using Illumina HumanHap1M Beadchips.

Genotypes for QIMR cases and controls were called with the Illumina BeadStudio software. Standard quality control procedures were applied as outlined previously (**Supplementary Methods**)[@R33]. Following exclusions 509,138 SNPs, 2,270 cases and 1,870 controls remained in the QIMR dataset. Oxford case and WTCCC2 control genotypes for all SNPs on the Illumina 670Quad BeadChip were called using Illuminus[@R34]. Following exclusions (**Supplementary Note**), 540,082 SNPs, 924 cases and 5,190 controls remained in the dataset. Post-QC genotype data from QIMR and Oxford were combined across 504,723 SNPs passing QC in both datasets.

Proportion of variation explained by all markers and predictive modelling {#S5}
-------------------------------------------------------------------------

Using a novel method[@R18] we estimated the proportion of variation explained by all markers. As genotyping artefacts can severely bias these estimates, the SNP data were subjected to more restrictive QC than utilised for the GWA analyses. SNPs with MAF \<0.01, missing rates \>0.001, *P* values for HWE \<10^−4^, and non-autosomal SNPs were excluded. Individuals with missing rates \>0.01, as well as one of any pair of individuals with estimated relationship \>0.05, were also excluded. After QC 2,235 cases and 1,827 controls with 454,193 SNPs were used for analysis of the QIMR data, and 921 cases and 5,158 controls with 453,663 SNPs were used for analysis of the Oxford data ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). When combining the data, we first pruned SNPs to a common set and excluded closely linked SNPs having r^2^\>0.5 in sliding 50 SNP windows using PLINK[@R35]. Again, one of any pair of individuals with estimated relationship \>0.05 was excluded. The combined analysis included 3,154 cases, 6,981 controls and 203,826 SNPs ([Table 1](#T1){ref-type="table"}).

Estimation of variation explained by all SNPs on the observed scale {#S6}
-------------------------------------------------------------------

Pairwise realized relationships were estimated as described previously[@R18],[@R36],[@R37]. Phenotypic observations (affected or unaffected, coded as 0 or 1) were modelled as a linear function of the sum of the additive effects due to all SNPs and residuals. For the combined analysis (QIMR and Oxford) cohort information was modelled as a covariate, which adjusts for the mean difference in the proportion of cases between the two cohorts. Variance components were estimated by residual maximum likelihood (REML)[@R38],[@R39].

The proportion of variation in case-control status explained by all SNPs simultaneously is not a heritability in the conventional sense. Firstly, the observations are on the risk scale, whereas heritability estimates for disease from pedigree data are usually parameterized on an underlying unobserved liability scale. Secondly, the proportion of cases in the study is not the same as the proportion of cases in the population so the estimate we obtain is with respect to a case-control population and not the population at large. Thirdly, conventional heritability from pedigree data captures the additive genetic variation due to all causal variants, whereas we capture only the variation due to causal variants tagged by SNPs on the arrays. Despite these caveats, the comparison of proportion of variation estimates and resulting *P* values from stage A and stage B cases remains valid because the test statistics would not change after scale transformation and ascertainment correction.

Case status prediction {#S7}
----------------------

The aim of the prediction analysis was to evaluate the aggregate effects of many variants of small effect. We summarized variation across nominally associated loci into quantitative scores and related the scores to disease state in independent samples. Although variants of small effect (e.g. genotype relative risk of 1.05) are unlikely to achieve even nominal significance, increasing proportions of "true" effects will be detected at increasingly liberal *P* value thresholds e.g. *P*\<0.1 (*i.e*. 10% of all SNPs), *P*\<0.2, etc. Using such thresholds we defined large sets of "allele specific scores" in the "discovery" sample of the Oxford dataset to generate risk scores for individuals in the "target" sample of the QIMR dataset. The term risk score is used instead of risk, as it is impossible to differentiate the minority of true risk alleles from non-associated variants. In the discovery sample we selected sets of allele specific scores for SNPs with *P*\<0.01, *P*\<0.05, *P*\<0.1, *P*\<0.2, *P*\<0.3, *P*\<0.4, *P*\<0.5 and *P*\<0.75. For each individual in the target sample we calculated the number of score alleles they possessed, each weighted by the log~10~ odds ratio from the discovery sample. To assess whether the aggregate scores reflect endometriosis risk, we tested for a higher mean score in cases compared to controls. Logistic regression was used to assess the relationship between target sample disease status and aggregate risk score. Nagelkerke's pseudo R-squared (henceforth R^2^) was used to assess the variance explained. Autosomal SNPs with MAF \<0.01 and SNPs in high linkage disequilibrium were pruned, resulting in a set of 225,955 SNPs.

GWA analyses {#S8}
------------

Although endometriosis is a condition exclusive to women, male and female controls were used in analyses of autosomal markers to maximise power, a method adopted previously in GWAs of breast cancer by the WTCCC[@R40],[@R41]. No significant allele frequency differences were detected between male and female controls. Moreover, the genome-wide significant SNPs rs12700667 (7p15) and rs7521902 (*WNT4*) showed no heterogeneity between male and female controls (*P* = 0.52 and *P* = 0.91, respectively). Cochran-Mantel-Haenszel (CMH) tests of association with "all" endometriosis or stage B alone were conducted in PLINK[@R35], with QIMR and Oxford data as different strata (to account for between population differences in baseline effect). Breslow-Day (BD) tests were conducted to check that the assumptions of the CMH test (*i.e.* same effect size across strata) were true.

Permutation approach to correct for multiple testing {#S9}
----------------------------------------------------

To address the non-independence between the "all" and stage B GWA analyses, we utilised a permutation approach where case/control status was randomly shuffled separately within the QIMR and Oxford datasets to break the relationship between phenotype and genotype, while retaining the relationship between "all" and stage B endometriosis. Of 1,000 permuted GWAs, recording the minimum *P* value for each SNP after analysis of both "all" and stage B cases, a *P* value ≤6.5 × 10^−8^ was obtained 50 times (genome-wide *P* ≤0.05). Hence rs12700667, rs7798431 and rs1250248 remain genome-wide significant after adjustment for multiple testing. Only one permuted GWAs produced an independent *P* value less than that observed for rs12700667 (*P* = 0.001, corrected for testing of both multiple markers and disease definitions).

Replication samples and genotyping {#S10}
----------------------------------

Endometriosis cases (2,392) for the replication samples were drawn from the US Nurses' Health Study (NHS) II[@R21],[@R42]. Replication controls were selected from two previous GWAs conducted in the NHSI and NHSII, including 1,142 postmenopausal, breast-cancer-free subjects from a breast cancer GWAs genotyped using the Illumina HumanHap 550 platform[@R20] and 1,129 subjects from a GWAs for kidney function[@R43] genotyped using Illumina 610 BeadChips. QC procedures have been described previously[@R20].

SNPs selected for replication were genotyped in the 2,392 NHS cases. Multiplex assays were designed using the Sequenom MassARRAY Assay Design software (version 3.0: Sequenom Inc., San Diego, CA, USA) and samples genotyped using standard methods[@R44],[@R45]. Post-laboratory QC was performed in PLINK[@R35].

Replication and meta-analyses {#S11}
-----------------------------

GWA SNPs reaching genome-wide significance were tested for replication in the NHS cohort. Also, to help direct further studies we examined SNPs if they surpassed the following thresholds: (1) *P* \<1.0 × 10^−4^ in the "all" endometriosis analysis (61 SNPs), or (2) any SNPs not already included with *P* \<1.0 × 10^−4^ in the stage B analysis *and P* \<1.0 × 10^−3^ in the "all" endometriosis analysis (14 SNPs). Genotype data were available for 2,271 NHS controls for 73 of these SNPs ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}).

We estimated the association ORs and *P* values for the NHS cohort using PLINK[@R35] ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}), performing CMH and BD tests with the QIMR, Oxford and NHS datasets as distinct clusters. Meta-analysis for the QIMR, Oxford, and Japanese[@R26] *P* values for 93 of the top 100 Japanese SNPs for which we had genotype data were conducted in GWAMA[@R46].

Power of the Japanese GWA study[@R26] including 1,423 endometriosis cases (unknown stage) and 1,318 controls to detect an OR of 1.20 for a risk allele frequency of 0.80 (HapMapII - JPT) of rs12700667, with a type I error of 1.8×10^−4^ (the threshold to select the top 100 SNPs for follow-up in their replication dataset), was calculated using the Genetic Power Calculator[@R47].

**URLs.** ECR Browser <http://ecrbrowser.dcode.org/>; SNPTESTv2 <http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html>; 1000 Genomes <http://www.1000genomes.org/>; HapMap <http://hapmap.ncbi.nlm.nih.gov/>

![Allele specific score prediction for (a) "all" endometriosis and (b) stage B endometriosis, using Oxford as the "discovery" and QIMR as the "target" dataset. Variance explained in the target dataset on the basis of allele specific scores derived in the discovery dataset for eight significance thresholds (*P*\<0.01, *P*\<0.05, *P*\<0.1, *P*\<0.2, *P*\<0.3, *P*\<0.4, *P*\<0.5, *P*\<0.75, plotted left to right in each study). The y-axis indicates Nagelkerke's pseudo R^2^ representing the proportion of variance explained. The number above each bar is the *P* value for the target dataset analysis. This figure shows that the results were not driven by a few highly associated regions, indicating a substantial number of common variants underlying disease.](ukmss-33578-f0001){#F1}

![Evidence for association with (a) "all" endometriosis and (b) stage B endometriosis across the chromosome 7 region following imputation using HapMap 3 and 1000 Genomes project CEU and TSI reference panels. SNP rs12700667 is represented by a purple diamond. All other SNPs are colour coded according to the strength of LD (as measured by r^2^) with rs12700667.](ukmss-33578-f0002){#F2}

###### 

Estimates of proportion of variation due to common genetic variants for "all" endometriosis and stage A or B disease using genome-wide SNP data from cases and controls

  -----------------------------------------------------------------------
  Phenotypes          Cases   Controls   Proportion of\   *P* value^a^
                                         variation (SE)   
  ------------------- ------- ---------- ---------------- ---------------
  All endometriosis   3154    6981       0.27 (0.04)      4.4 × 10^−16^

  Stage B             1347    6981       0.34 (0.04)      4.4 × 10^−16^

  Stage A             1666    6981       0.15 (0.04)      2.6 × 10^−4^
  -----------------------------------------------------------------------

Proportion of variation and associated *P* values for the likelihood ratio test were estimated using a linear mixed model incorporating 203,826 SNPs from the GWA panel after additional QC. Case and control numbers are slightly lower than for the GWA analyses due to the stricter QC measures (**Online Methods**). Stage A and stage B estimates of the variance explained are significantly different from each other (*P* = 1.8 × 10^−3^, using a two sample t-test which is conservative since the control samples are the same). Results were verified by prediction of individual genetic risk using QIMR and Oxford as alternate "discovery" and "target" datasets ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

###### 

GWA, replication and meta-analysis results for rs12700667

  ------------------------------------------------------------------------------------------------------------------------------------------
  Analysis                                            Number of\       Risk allele (A)\   *P* value      OR (95% CIs)       Heterogeneity\
                                                      Cases/Controls   frequency in\                                        test *P* value
                                                                       controls                                             
  --------------------------------------------------- ---------------- ------------------ -------------- ------------------ ----------------
  1\. GWA -- All endometriosis                                                                                              

  QIMR                                                2270/1870        0.73               1.5 × 10^−5^   1.25 (1.13-1.38)   \-

  Oxford                                              924/5190         0.74               3.9 × 10^−3^   1.19 (1.06-1.34)   \-

  Combined                                            3194/7060        0.74               2.6 × 10^−7^   1.22 (1.13-1.32)   0.56

  2\. GWA -- Stage B                                                                                                        

  QIMR                                                910/1870         0.73               8.3 × 10^−7^   1.40 (1.22-1.60)   \-

  Oxford                                              454/5190         0.74               4.2 × 10^−4^   1.35 (1.14-1.60)   \-

  Combined                                            1364/7060        0.74               1.5 × 10^−9^   1.38 (1.24-1.53)   0.75

  3\. Replication NHSII --\                           2392/2271        0.73               1.2 × 10^−3^   1.17 (1.06-1.28)   \-
  All endometriosis [a](#TFN1){ref-type="table-fn"}                                                                         

  4\. Meta-analysis --\                               5586/9331        0.74               1.4 × 10^−9^   1.20 (1.13-1.27)   0.64
    All Endometriosis (1+3)                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------

Stage was unknown for cases in the NHSII replication cohort, though estimated to include \~40% stage B[@R21].
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